Printer Friendly

BIOSPECIFICS TECHNOLOGIES ANNOUNCES LICENSEE'S DOUBLING OF SALES

 LYNBROOK, N.Y., July 9 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) at its annual stockholders' meeting reported that its U.S. licensee of Collagenase Ointment, trade named "Collagenase Santyl," already has had sales in the first six months of 1993 in excess of sales for all of 1992. As a consequence of this tremendous sales growth, the licensee has more than doubled the number of its nurse educators. These nurse educators have been teaching nurses in nursing and hospital facilities the importance of this therapy in life- threatening conditions and the cost effectiveness of the ointment as a debriding agent for pressure ulcers. The doubling of sales from existing representatives is expected to get a still further boost from these new nurse educators, after a training period. The licensee also reported that it is looking to make inroads in the use of the ointment for vascular and diabetic ulcers, as yet a mostly untapped market. In addition, as previously reported, the results of a major study of the use of the ointment in the treatment of burns will appear in the major peer reviewed burn journal and will be presented to the American College of Surgeons in October 1993.
 Edwin H. Wegman, president, reported on efforts to secure approvals and licensees for the product in other countries and on the progress being made with other potential products in the research and development stage.
 -0- 7/9/93
 /CONTACT: Edwin H. Wegman, president of BioSpecifics Technologies Corp., 516-593-7000, or Sam Witchel of Scharff, Witchel & Co., Inc., 212-983-1060, for BioSpecifics Technologies Corp./
 (BSTC)


CO: BioSpecifics Technologies Corp. ST: New York IN: HEA SU:

MP-OS -- NY021 -- 9846 07/09/93 10:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1993
Words:280
Previous Article:METRO TEL REPORTS SETTLEMENT OF LAW SUIT AGAINST HARRIS CORPORATION
Next Article:AMERICAN EXPLORATION COMPANY ANNOUNCES SALE OF CANADIAN PROPERTIES
Topics:


Related Articles
BIOSPECIFICS TECHNOLOGIES ANNOUNCES FIRST QUARTER FISCAL 1993 RESULTS
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SECOND QUARTER AND RECORD SIX MONTHS REVENUES AND INCOME
BIOSPECIFICS TECHNOLOGIES ISSUES STATEMENT ON OINTMENT SALES
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES NINE MONTHS REVENUES AND INCOME; THIRD QUARTER RESULTS
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES EXTENSION OF NUCLEOLYSIN DISTRIBUTION AGREEMENT
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES FIRST QUARTER FISCAL 1994 RESULTS
BIOSPECIFICS TECHNOLOGIES ANNOUNCES ITS THIRD CONSECUTIVE QUARTER OF INCREASED REVENUES AND EARNINGS
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES INCREASES IN PRODUCTION AND FORECAST
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES COLLAGENASE OINTMENT CONTRACT IN ITALY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters